ZYME Earnings Preview

FDA approval looms as insider exits $70M position

The financing solves Zymeworks' runway without dilution, and zanidatumab's Phase 3 data (statistically significant PFS benefit, median OS exceeding two years) provides clinical validation for launch. But Redmile's exit — reducing its stake to just 0.95% of its portfolio — suggests the insider sees limited upside between now and H2 2026. The stock's 60% gain has already priced in much of the Phase 3 optimism; the real test is whether real-world uptake justifies the royalty structure's cash flow assumptions.

Watch: FDA approval timing in H2 2026 and initial launch ramp will determine whether the royalty deal delivers promised cash flow. Watch for further insider selling or buying — it's the clearest signal of whether management believes the commercial upside has further to run.